CN1169529C - Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process - Google Patents
Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process Download PDFInfo
- Publication number
- CN1169529C CN1169529C CNB011295074A CN01129507A CN1169529C CN 1169529 C CN1169529 C CN 1169529C CN B011295074 A CNB011295074 A CN B011295074A CN 01129507 A CN01129507 A CN 01129507A CN 1169529 C CN1169529 C CN 1169529C
- Authority
- CN
- China
- Prior art keywords
- silver
- grams
- nanometer
- nano
- prostatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229910052709 silver Inorganic materials 0.000 title claims abstract description 25
- 239000004332 silver Substances 0.000 title claims abstract description 25
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 18
- 230000000845 anti-microbial effect Effects 0.000 title claims description 13
- 206010061218 Inflammation Diseases 0.000 title claims description 11
- 238000009776 industrial production Methods 0.000 title 1
- 239000000843 powder Substances 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims abstract description 9
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical group [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910001923 silver oxide Inorganic materials 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 20
- 230000000844 anti-bacterial effect Effects 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000005516 engineering process Methods 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 11
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 10
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 claims description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 9
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 9
- 238000001228 spectrum Methods 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 6
- 208000014617 hemorrhoid Diseases 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000002344 surface layer Substances 0.000 abstract description 2
- 230000003260 anti-sepsis Effects 0.000 abstract 2
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 208000017497 prostate disease Diseases 0.000 abstract 1
- 230000028327 secretion Effects 0.000 description 24
- 239000004615 ingredient Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000002270 dispersing agent Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000607522 Aeromonas sobria Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- XPHUNVSXINXQTD-UHFFFAOYSA-N N1=CC=CC2=CC=CC=C12.O1C=CC=C1 Chemical compound N1=CC=CC2=CC=CC=C12.O1C=CC=C1 XPHUNVSXINXQTD-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 241000933979 bacterium 14 Species 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 230000001354 painful effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
- A61L2/238—Metals or alloys, e.g. oligodynamic metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Heart & Thoracic Surgery (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention discloses an antisepsis and dephlogistication gel for nano-silver prostatitis, which contains pharmaceutically acceptable addition agents and antisepsis nano-silver micro powder for preventing broad-spectrum aggregation, wherein the particle diameter of the nano-silver is from 1 to 100 nanometers, the surface layer of the nano-silver is silver oxide of 2 to 8 nanometers, and the core of the nano-silver is the element silver. The product of the present invention can be used for treating male prostatitis and reliving the pain of organic prostate diseases of the male senile persons, and has excellent curative effect on both internal hemorrhoids and external hemorrhoids of human bodies.
Description
The invention relates to a kind of antibacterials that adopt nanometer silver, more particularly, is about a kind of nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and industrialized producing technology and application thereof.
Male prostatitis is owing to the thicker lipid layer of prostate outer wrapping one deck causes.Thereby when using existing Drug therapy, its medicine active ingredient is difficult to penetrate this lipid layer and arrives lesions position.Find that through modern medicine study the active drug composition that can arrive prostate focus position only is 1/1000 of using dosage, thus the unsatisfactory curative effect in treatment, a real difficult problem that belongs to domestic and international medical circle.Up to now, the specific drug that does not still have the treatment male prostatitis in the world.
One of purpose of the present invention provides a kind of nanometer silver antimicrobial antiphlogistic gel for the treatment of male prostatitis.
Two of purpose of the present invention provides a kind of industrialized producing technology for the treatment of the nanometer silver antimicrobial antiphlogistic gel of male prostatitis.
This and other purpose of the present invention will and be described by following detailed description and further embody and illustrate.
In the present invention, nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis of the present invention, it is except that containing the additives of pharmaceutically accepting, also contain aggregation-preventing nanometer wide-spectrum antibacterial silve powder, the particle diameter of this nanometer silver is 1～100 nanometer, and the top layer is the silver oxide of 2～8 nanometers, and core is an elemental silver; Described pharmaceutically acceptable additives comprise monomer carrier, surfactant, dispersant and transdermal enhancer etc.
In nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis of the present invention, described reagent combination is (by 10 kilograms of gelometers):
A, stearyl alcohol 200～600 grams, PEG400 2000～8000 grams,
PEG3350 2000～6000 grams;
1000～2000 milliliters of B, pure water, 400～1200 milliliters of glycerol,
Nano silver powder 10～30 grams, sodium laurylsulfate 20～50 grams.
In the present invention, described monomer carrier is natural or synthetic high molecular gel rubber material, surfactant is ionic surface active agent and non-ionic surface active agent, dispersant is high molecular polymer class, surfactant-based and organic acid dispersant, and transdermal enhancer is natural or synthetic polymer and synthetic bullet colloid.
The industrialized producing technology of nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis of the present invention, comprise by proportional quantity pure water and glycerol, sodium laurylsulfate mixing and stirring, the adding nano silver powder also stirs, under 60～70 ℃ of heating and stirring condition, add stearyl alcohol, PEG400, PEG3350, mix homogenizing at last and make it even, be cooled under stirring and solidify, packing gets final product.
Product of the present invention also can have relief of symptoms, reduce painful effect the organic prostatosis of elderly men except being used for the treatment of prostatitis.In addition, product of the present invention has very excellent antibacterial ability, so, to the inside and outside hemorrhoid of human body antiinflammatory is arranged equally, the pain of dispelling excellent curative effect.
In the present invention, employing oneself is applied in person, application number is 01110767.7, and name is called the prepared nano silver powder of aggregation-preventing nanometer wide-spectrum antibacterial silve powder.
Having adopted the inventor in the present invention is the spice of the product described in 01110767.7-wide-spectrum antiseptic nanometer silver micropowder as antimicrobial inflammation-relieving gel for curing prostatitis of the present invention at number of patent application.The silver particle that is loaded with on this micropowder, detecting its particle diameter through scanning tunneling microscope is 1～100 nanometer, see the Fig. 4 (Fig. 1 in the accompanying drawing, 2,3 is for handling without anti-centralizing technique) in the accompanying drawing, the excellent properties that the antibacterial functions of this kind nano silver powder shows sees attached list 1,2
Subordinate list 1 is detected by medical test center Microbiological Lab of the Chinese People's Liberation Army.
Subordinate list 2 is detected by Huashan hospital of Shanghai Medical Univ Bacteriology Room.
Antibiotic mechanism of the present invention is as follows
Therefore nanometer silver is by the most classical antibiotic mechanism, in the enzyme of depending on for existence in the thalline-SH group displacement one-tenth-SAg, makes the enzyme loss of activity and cause pathogenic bacterium death, and its product is enzyme-2SAg and H
2There is not the secondary paathogenic factor in O.
In sum, the present invention makes product-nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis of the present invention have excellent specific function owing to used nano silver powder as spice.Show as outstanding antibacterial ability, has a broad antifungal spectrum all has tangible antibacterial functions to gram-positive bacteria, gram-negative bacteria, fungus, anaerobe.Especially to the same tool sterilizing ability of drug resistance pathogenic bacterium, and avirulence, no anaphylaxis, nonirritant, hydrophilic-chance water sterilizing power is stronger.So rapid-action, the good effect of product of the present invention has no side effect.Product of the present invention can pass through rectally.And the particle diameter of nanometer silver is 1～100 nanometer, because the particle diameter of silver particle reduces, the atomic number that is in surface layer is increased sharply, cause former coordination deficiency, unsaturated bond exposes and increases, the surface energy of atom increases, so have extremely strong chemism, so adding particle diameter is that these nanometer silvers of nanoscale have the ability of well oozing thoroughly, can penetrate the lipid layer of human body prostate outsourcing, the sterilizing function of the excellence of while nanometer silver, because these comprehensive favorable factors, so nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis of the present invention has solved a prostatitic treatment difficult problem preferably.Simultaneously old man's organic prostatosis is also had the effect of reduction of patient misery, the inside and outside hemorrhoid to human body have excellent treatment function equally in addition.
The present invention has used aggregation-preventing nanometer wide-spectrum antibacterial silve powder as medicine, and its silver content is according to American Pharmacopeia (USP), and British Pharmacopoeia (BP) institute periodical method is determined as 0.1-200 milligram/gram.
In the production technology used adjuvant in respect of:
Pure water, glycerol, sodium laurylsulfate, stearyl alcohol, Polyethylene Glycol (PEG) etc. (the monomer carrier in this technology is natural and the synthetic high polymer gel rubber material, is preferably Polyethylene Glycol (PEG), is commercially available conventional additives).
Activating agent is ionic surface active agent and non-ionic surface active agent, and dispersant is the high molecular polymer class, surfactant-based and organic acid, activating agent and dispersant are preferably sodium laurylsulfate, transdermal enhancer is natural and synthetic polymer, and the synthetic colloid that plays is preferably glycerol.
Above adjuvant or additive all can be buied from market, further, also can adopt the conventional similar product that uses in the industry.
Technological process of the present invention
Below further specify the present invention by specific embodiment, can not limit the scope of the invention but embodiment only is used for explanation, if not refer in particular to all parts in the present invention, measure the heavy unit be based on gross weight, " M " is molar concentration.
Example 1:
By application number is 01110767.7; name is called: the prepared described method of nano silver powder of aggregation-preventing nanometer wide-spectrum antibacterial silve powder prepares aggregation-preventing nanometer wide-spectrum antibacterial silve powder; this embodiment is only with the son explanation, not in the claim protection domain of present patent application.
By following amount preparating liquid (by 10 kilograms of carriers)
A、AgNO3 0.5M， NH3·H2O 0.3M， NaOH 0.1M，
Adding water to cumulative volume is 500 liters;
B, glucose 4M, HNO3 0.1M boiled 1～5 minute, and the cooling back adds ethanol makes into 10M, and volume is 50 liters.
Carrier (Medulla Junci) is cleaned, added the medical alcohol and the distilled water (the two ratio is 1: 15) of 98% concentration, with the carrier submergence, vacuum extraction to carrier does not have organic principle and impurity, and extract is for using.
Can put into 10 kilograms of carriers of handling well (Medulla Junci) for dipping usefulness with placing behind 10 parts+1 part B (V/V) mixing after 10～40 minutes.Dipping back supercharging homogenizing makes medicinal liquid and carrier mix homogeneously, enter reactor and carry out also adding continuously in chemistry and the physical treatment dispersant OP-10 (under ventilation condition and under the agitation as appropriate condition), be pale brown color to Medulla Junci, then through clean, dry, pulverize and promptly get aggregation-preventing nanometer wide-spectrum antibacterial silve powder of the present invention.
Example 2
In 10 kilograms of gel contents
Ingredients:
A: stearyl alcohol 250 grams, PEG400 5000 grams, PEG3350 3000 grams,
B: 1200 milliliters of pure water, sodium laurylsulfate 4 grams, 550 milliliters of glycerol,
Nano silver powder 20 grams;
Technology:
The B ingredients is inserted the heated and stirred reactor, after stirring and being heated to 60～65 ℃, add the A ingredients and keep temperature and stir, make to mix evenly, enter mixed homogenizer and keep temperature, when treating that mixed homogenizing is finished, be cooled under stirring condition and solidify, packing gets final product.
Example 3
In 10 kilograms of gel contents
Ingredients:
A: stearyl alcohol 400 grams, PEG400 4500 grams, PEG3350 3000 grams,
B: 1700 milliliters of pure water, 650 milliliters of glycerol, sodium laurylsulfate 4 grams,
Nano silver powder 32 grams;
Technology:
The B ingredients is inserted the heated and stirred reactor, after stirring and being heated to 60～65 ℃, add the A ingredients and keep temperature and stir, make to mix evenly, enter mixed homogenizer and keep temperature, when treating that mixed homogenizing is finished, be cooled under stirring condition and solidify, packing gets final product.
Example 4
In 10 kilograms of gel contents
Ingredients:
A: stearyl alcohol 200 grams, PEG400 3000 grams, PEG3350 2500 grams,
B: 1100 milliliters of pure water, 450 milliliters of glycerol, sodium laurylsulfate 4 grams,
Nano silver powder 12 grams;
Technology is with example 3.
Example 5
In 10 kilograms of gel contents
Ingredients:
A: stearyl alcohol 600 grams, PEG400 7500 grams, PEG3350 5500 grams,
B: 1900 milliliters of pure water, 1150 milliliters of glycerol, sodium laurylsulfate 4 grams,
Nano silver powder 28 grams;
Technology is with example 3.
Example 6
In 10 kilograms of gel contents
Ingredients:
A: stearyl alcohol 500 grams, PEG400 5500 grams, PEG3350 3500 grams,
B: 1600 milliliters of pure water, 850 milliliters of glycerol, sodium laurylsulfate 4 grams,
Nano silver powder-25 gram;
Technology is with example 3.
Table 1
The antibacterial result of PNSM and 8 kinds of antibacterials
PNSM and contrast ■ bacteriostatic diameter (mm) antibacterials MIC method drug sensitivity tests
Bacterium name source
The negative benzene azoles nitrogen benzyl cephalo cephalo cephalo celebrating of washing washing macro ring third
Do not wash erythromycin
The 50 times 100 times husky stars of red his the pyridine mycin of contrast XiLin, XiLin azoles quinoline furan
Staphylococcus aureus ATCC25923 18 15 15 7 24 S S S S S S S
Escherichia coli ATCC25922 13 13 12 7 10 S S S S S S
Pseudomonas aeruginosa ATCC27853 12 12 12 76 S S S
Bacillus perfringens CMCC (B) 6460610
Staphylococcus aureus (MRSA) secretions 17 15 15 76 R R R R R R R
Staphylococcus epidermidis (MRSE) secretions 18 15 16 76 R R R R R R R
Micrococcus scarlatinae secretions 98876 S S S S S S S
Gonorrhea is mycete secretions 10 10 10 7 31 S S S S S S how
Escherichia coli secretions 17 14 14 76 R R R R R R
Enterobacter cloacae secretions 9887 11 R R R R R R
Clostridium perfringen secretions 14 12 13 76 R R R R R R
Pseudomonas aeruginosa secretions 15 15 15 76 R R R R R R
Stenotrophomonas maltophilia secretions 14 13 14 76 R R R S R S
Acinetobacter bauamnnii secretions 13 12 12 7 19 R R R S S S
Klebsiella Pneumoniae secretions 15 14 14 76 R R R S R S
Serratia marcesens secretions 16 13 14 76 R R R R R S
Take labor ground citrobacter secretions 11 10 11 76 R R R R R R
Thunder amasss Pu Luoweideng bacterium secretions 15 13 13 76 R R R S R S
Aeromonas hydrophila secretions 13 11 13 7 16 R R R S R S
Aeromonas sobria secretions 14 12 12 7 17 R I I S R S
Vibrio vulnificus secretions 17 15 15 76 R R R S I S
Proteus mirabilis secretions 11 10 10 79 R R R S R R
Proteus vulgaris secretions 11 9 11 76 R R R S R R
Pan Shi Bacillus proteus secretions 10 9 10 76 R R I S R S
Candida albicans secretions 21 20 20 76
Oidium tropicale secretions 18 17 18 76
Candida parapsilosis secretions 20 19 20 76
Smooth ball is intended pure female bacterium secretions 27 26 26 76
Annotate: the responsive I of S.: the R of intermediary: drug resistance
Table 2
The blank AB fabric of bacterial strain PNSM
Fabric is washed 20 sub-high pressures and is not washed height and compress and wash and wash for 20 times 50 times
Bacillus pyocyaneus----15 13 16 16
Staphylococcus aureus----15 17 15 15
Escherichia coli----13 14 18 15
MRSA - - - - 14 14 17 15
Wax-shaped bacillus---11 13 13 15 15
Vibrio vulnificus----16 16 16 17
Candida albicans-21--11 11 11 11
B group's Hemolytic streptococcus----11 11 12 11
Pseudomonas Maltophilia----12 12 15 14
Nitrate-negative bacillus----14 14 13 15
Moscow' paratyphi C-12--12 14 19 14
Arizona bacterium----14 14 15 14
Citrobacter----14 14 15 13
Pneumobacillus----13 13 17 13
Bacillus subtilis----12 12 12 12
Morganella morganii---10 12 12 12 12
Alcaligenes faecalis----14 12 16 16
Si Shi Pu Tufeideng Salmonella----12 12 14 13
Enterobacter cloacae----13 13 13 13
Gonococcus----11 11 11 11
Above result shows that PNSM all has inhibitory action to 20 strain antibacterials, and the antibacterial that commute develops immunity to drugs, as staphylococcus aureus persister (MRSA), bacillus pyocyaneus, Pseudomonas Maltophilia and nitrate-negative bacillus etc. all have inhibitory action, high pressure and wash 20 times and 50 times after all with without the washing the same, bacteriostasis there is not obvious influence, and the AB fabric is after washing 20 times, all can not suppress above antibacterial, this shows that the scope of restraining fungi of PNSM extensively and not can influence fungistatic effect because of washing than AB fabric.
Claims (2)
1, a kind of nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis, it is characterized in that also containing aggregation-preventing nanometer wide-spectrum antibacterial silve powder except that containing the additives of pharmaceutically accepting, the particle diameter of this nanometer silver is 1～100 nanometer, the top layer is the silver oxide of 2～8 nanometers, and core is an elemental silver; Described reagent combination is counted by 10 kilograms of gels:
A, stearyl alcohol 200～600 grams, PEG400 2000～8000 grams,
PEG3350 2000～6000 grams;
1000～2000 milliliters of B, pure water, 400～1200 milliliters of glycerol,
Nano silver powder 10～30 grams, sodium laurylsulfate 20～50 grams.
2, the industrialized producing technology of nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis as claimed in claim 1, it is characterized in that by proportional quantity pure water and glycerol, sodium laurylsulfate mixing and stirring, the adding nano silver powder also stirs, under 60～70 ℃ of heating and stirring condition, add stearyl alcohol, PEG400 and PEG3350, mixing homogenizing at last makes it even, be cooled under stirring and solidify, packing gets final product.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011107677A CN1179646C (en) | 2001-04-20 | 2001-04-20 | Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process |
| CN01223000U CN2479952Y (en) | 2001-04-20 | 2001-05-08 | Nm silver plaster for trauma |
| CNB011295074A CN1169529C (en) | 2001-04-20 | 2001-06-22 | Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process |
| CN01129505A CN1328819A (en) | 2001-04-20 | 2001-06-22 | Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process |
| CNB018231578A CN1224479C (en) | 2001-04-20 | 2001-11-26 | Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application |
| PCT/CN2001/001584 WO2002090025A1 (en) | 2001-04-20 | 2001-11-26 | Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011107677A CN1179646C (en) | 2001-04-20 | 2001-04-20 | Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process |
| CN01223000U CN2479952Y (en) | 2001-04-20 | 2001-05-08 | Nm silver plaster for trauma |
| CNB011295074A CN1169529C (en) | 2001-04-20 | 2001-06-22 | Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process |
| CN01129505A CN1328819A (en) | 2001-04-20 | 2001-06-22 | Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1328827A CN1328827A (en) | 2002-01-02 |
| CN1169529C true CN1169529C (en) | 2004-10-06 |
Family
ID=27429906
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011107677A Expired - Fee Related CN1179646C (en) | 2001-04-20 | 2001-04-20 | Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process |
| CN01223000U Expired - Lifetime CN2479952Y (en) | 2001-04-20 | 2001-05-08 | Nm silver plaster for trauma |
| CN01129505A Pending CN1328819A (en) | 2001-04-20 | 2001-06-22 | Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process |
| CNB011295074A Expired - Fee Related CN1169529C (en) | 2001-04-20 | 2001-06-22 | Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process |
| CNB018231578A Expired - Fee Related CN1224479C (en) | 2001-04-20 | 2001-11-26 | Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011107677A Expired - Fee Related CN1179646C (en) | 2001-04-20 | 2001-04-20 | Aggregation-preventing nanometer wide-spectrum antibacterial silve powder and its inductrial production process |
| CN01223000U Expired - Lifetime CN2479952Y (en) | 2001-04-20 | 2001-05-08 | Nm silver plaster for trauma |
| CN01129505A Pending CN1328819A (en) | 2001-04-20 | 2001-06-22 | Nanometer silver antimicrobial inflammation-relieving film for curing gynecopathy and its production process |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018231578A Expired - Fee Related CN1224479C (en) | 2001-04-20 | 2001-11-26 | Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod and its application |
Country Status (2)
| Country | Link |
|---|---|
| CN (5) | CN1179646C (en) |
| WO (1) | WO2002090025A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457084C (en) * | 2006-08-04 | 2009-02-04 | 武汉正午阳光医药生物科技有限公司 | Nanometer silver type external use antibiotic gel for female external use and its prepn. method |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7137968B1 (en) | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
| US6719987B2 (en) | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
| US20030185901A1 (en) | 2000-07-27 | 2003-10-02 | Burrell Robert E. | Methods of treating conditions with a metal-containing material |
| US7255881B2 (en) | 2000-07-27 | 2007-08-14 | Nucryst Pharmaceuticals Corp. | Metal-containing materials |
| US7008647B2 (en) | 2001-04-23 | 2006-03-07 | Nucryst Pharmaceuticals Corp. | Treatment of acne |
| US7427416B2 (en) | 2000-07-27 | 2008-09-23 | Nucryst Pharmaceuticals Corp. | Methods of treating conditions using metal-containing materials |
| US7001617B2 (en) | 2001-04-23 | 2006-02-21 | Nueryst Pharmaceuticals Corp. | Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals |
| WO2002009729A2 (en) | 2000-07-27 | 2002-02-07 | Nucryst Pharmaceuticals Corp. | Treatment of hyperproliferative skin disorders and diseases |
| US6989157B2 (en) | 2000-07-27 | 2006-01-24 | Nucryst Pharmaceuticals Corp. | Dry powders of metal-containing compounds |
| AU2002303438B2 (en) | 2001-04-23 | 2007-10-25 | Smith & Nephew (Overseas) Limited | Therapeutic treatments using the direct application of antimicrobial metal compositions |
| US7201925B2 (en) | 2002-04-23 | 2007-04-10 | Nueryst Pharmaceuticals Corp. | Treatment of ungual and subungual diseases |
| CN1627901A (en) * | 2002-06-03 | 2005-06-15 | 深圳市清华源兴生物医药科技有限公司 | Nano composite material of silver |
| DE10346387A1 (en) * | 2003-10-07 | 2005-06-09 | Henkel Kgaa | Antimicrobial equipment of bathroom and toilet articles |
| EP1616926A1 (en) | 2004-07-15 | 2006-01-18 | Interuniversitair Microelektronica Centrum ( Imec) | Slurry composition and method for chemical polishing of copper integrated with tungsten based barrier metals |
| US8399027B2 (en) | 2005-04-14 | 2013-03-19 | 3M Innovative Properties Company | Silver coatings and methods of manufacture |
| CN100386369C (en) * | 2005-06-03 | 2008-05-07 | 陈汝霖 | New type products of Nano silver latex, and preparation method |
| US20100203088A1 (en) * | 2005-06-08 | 2010-08-12 | Khandelwal Sanjeev | Silver Nanoparticle Dispersion Formulation |
| US20070166399A1 (en) | 2006-01-13 | 2007-07-19 | 3M Innovative Properties Company | Silver-containing antimicrobial articles and methods of manufacture |
| CN101466388A (en) * | 2006-06-16 | 2009-06-24 | 默克专利股份有限公司 | Antimicrobial carbon |
| CN100396290C (en) * | 2006-11-03 | 2008-06-25 | 段炬红 | External use anti-bacteria foaming agent for gynecology |
| CN101049279B (en) * | 2007-04-30 | 2010-06-23 | 东莞市拓扑光电科技有限公司 | Antibacterial shampoo of Nano silver, and preparation method |
| WO2009085651A1 (en) | 2007-12-20 | 2009-07-09 | Nucryst Pharmaceuticals Corp. | Metal carbonate particles for use in medicine and methods of making thereof |
| US8815307B2 (en) * | 2008-12-31 | 2014-08-26 | Colotex Industrial Co., Ltd. | Process for producing porous polymer masterbatch and fiber thereof having anti-bacterial and odor eliminating functions |
| CN102430761A (en) * | 2011-12-12 | 2012-05-02 | 池州学院 | Preparation method for water-soluble nano silver for killing oncomelania hupensis |
| CN103341642B (en) * | 2013-07-26 | 2015-12-02 | 莆田学院 | A kind of cellulose green syt method of nano silver particles |
| CN103688996B (en) * | 2013-11-28 | 2014-12-10 | 太原理工大学 | Method for preparing silver-loaded antibacterial agent by using waste cotton fiber |
| CN105640986A (en) * | 2014-11-28 | 2016-06-08 | 广东工业大学 | Silver nanoparticle composition for control of lung cancer and prostate cancer |
| CN107598186B (en) * | 2017-08-30 | 2019-08-20 | 苏州工业园区格云环保新材料有限公司 | A kind of preparation method of nano silver and its fumigation liquid |
| CN109137490A (en) * | 2018-06-27 | 2019-01-04 | 苏州市天翱特种织绣有限公司 | A kind of antibacterial modified method of cotton fiber |
| EP3920726A1 (en) * | 2019-02-05 | 2021-12-15 | Griffith Foods International Inc. | Anti-caking agent or flow agent for a seasoning, pharmaceuticals or nutraceuticals |
| CN111763365B (en) * | 2020-07-17 | 2022-09-02 | 安信纳米生物科技（珠海）有限公司 | Antibacterial fresh-keeping material containing nano-silver and preparation method thereof |
| CN113664213B (en) * | 2021-08-04 | 2023-11-21 | 湖南伟方生命科技有限公司 | Preparation method and application of nano silver antibacterial liquid |
| CN114028318B (en) * | 2021-10-14 | 2023-11-21 | 湖南伟方生命科技有限公司 | Male antibacterial liquid and preparation method and application thereof |
| CN115137681A (en) * | 2022-06-23 | 2022-10-04 | 深圳市黄田荔枝品牌发展有限公司 | Litchi mask and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07173022A (en) * | 1993-12-17 | 1995-07-11 | Asahi Chem Ind Co Ltd | Antimicrobial agent |
| CN1058868C (en) * | 1994-11-26 | 2000-11-29 | 广州安信生物科技发展有限公司 | Long-effect and broad-spectrum antibiotic granules and its production |
| JP4025839B2 (en) * | 1996-09-12 | 2007-12-26 | Ｄｏｗａエレクトロニクス株式会社 | Silver powder and method for producing silver powder |
| CN1161511C (en) * | 1999-07-27 | 2004-08-11 | 蒋建华 | Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method |
| CN1266761A (en) * | 2000-03-23 | 2000-09-20 | 南京大学 | Process for preparing nm-class silver powder |
-
2001
- 2001-04-20 CN CNB011107677A patent/CN1179646C/en not_active Expired - Fee Related
- 2001-05-08 CN CN01223000U patent/CN2479952Y/en not_active Expired - Lifetime
- 2001-06-22 CN CN01129505A patent/CN1328819A/en active Pending
- 2001-06-22 CN CNB011295074A patent/CN1169529C/en not_active Expired - Fee Related
- 2001-11-26 CN CNB018231578A patent/CN1224479C/en not_active Expired - Fee Related
- 2001-11-26 WO PCT/CN2001/001584 patent/WO2002090025A1/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457084C (en) * | 2006-08-04 | 2009-02-04 | 武汉正午阳光医药生物科技有限公司 | Nanometer silver type external use antibiotic gel for female external use and its prepn. method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1328827A (en) | 2002-01-02 |
| CN1322474A (en) | 2001-11-21 |
| CN1505551A (en) | 2004-06-16 |
| CN1224479C (en) | 2005-10-26 |
| CN2479952Y (en) | 2002-03-06 |
| CN1328819A (en) | 2002-01-02 |
| CN1179646C (en) | 2004-12-15 |
| WO2002090025A1 (en) | 2002-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1169529C (en) | Nanometer silver antimicrobial inflammation-relieving gel for curing prostatitis and its industrial production process | |
| CN1161511C (en) | Long-acting wide-spectrum antiseptic nanometer silver fabric and its making method | |
| CN1147640C (en) | Antibacterial fabric containing nm-class silver powder and its making method | |
| US20120308623A1 (en) | Composition comprising nanoparticles of ti02 | |
| US20220354985A1 (en) | Anti-Microbial Medical Materials and Devices | |
| Gao et al. | Efficient antimicrobial silk composites using synergistic effects of violacein and silver nanoparticles | |
| CN1788568A (en) | Quick-effective iodine disinfectant and production method thereof | |
| CN1899291A (en) | External use antifungal compound composition and its use | |
| CN1183285C (en) | Aggregation-preventing wide-spectrum nanometer antibiotic silver yarn and its industrial production process | |
| CN1685828A (en) | Silver-zinc particle nano pore composite material and its application in surface anti infection region | |
| CN1131068C (en) | Composite lysostaphin enzyme spray for oral cavity and its preparing process | |
| CN1751577A (en) | Composite sterilizing agent contg. silver and zinc, prepn. method and application thereof | |
| CN1672689A (en) | Nano silver antiseptic gel for treating women's genital tract infection and its prepn and application | |
| CN1369206A (en) | Nano Silver sterilizing gel, its preparing method and use | |
| Samrat et al. | Evaluation of improved antifungal activity of fluconazole–silver nanoconjugate against pathogenic fungi | |
| CN1484959A (en) | Sterilization formulation and wet tissue, preparation method and use | |
| CN1156624C (en) | Aggregation-preventing wide-spectrum antiseptic nanometer silver knitted article and fabric and their industrial production process | |
| CN1267105C (en) | Broad spectrum bacteriostat and sterilizing of silicate based angstrom silver ion nano porous composite mateiral | |
| CN1185934C (en) | Disinfectant lotion for body's vulva and vagina | |
| CN1286525C (en) | New type pellicle of ocean lysozyme and preparation method | |
| CN1307881C (en) | New use of bactericide H4Ag 206 containing silver and its prepared medicine | |
| CN1507782A (en) | Nano-silver loaded natural plant composite antibacterial material and preparing method thereof | |
| CN1269479C (en) | Externally used liquid preparation containing fibrauretine and its application on genital tract, oral cavity and upper respiratory tract | |
| CN109464455A (en) | A kind of creme for preventing and treating pet body surface bacterium and fungi | |
| CN1593453A (en) | Sterilizing and bacteria inhibiting pharmaceutical composition and its formulation and preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZHU LI Effective date: 20050225 Owner name: TSINGHUA YUANXING BIO-PHARM TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHU HONGJUN |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20050225 Address after: 518057, Shenzhen hi tech Development Zone, North District, Nanshan District Road Patentee after: Tsinghua Yuanxing Biomedicine Tech Co., Ltd., Shenzhen Address before: Changning District Shanghai Fahuazhen 200000 No. 236 Co-patentee before: Zhu Chi Patentee before: Zhu Hongjun |
|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Lingjiang Document name: Special business review memo |
|
| C56 | Change in the name or address of the patentee |
Owner name: SHENZHEN YUANXING BIO-PHARM CO., LTD. Free format text: FORMER NAME: TSINGHUA YUANXING BIOMEDICINE TECH CO., LTD., SHENZHEN |
|
| CP03 | Change of name, title or address |
Address after: 518057 Lang Shan Road, North District, Nanshan District hi tech Development Zone, Guangdong, Shenzhen Patentee after: Shenzhen Yuanxing Bio-Pharm Co., Ltd. Address before: 518057, Shenzhen hi tech Development Zone, North District, Nanshan District Road Patentee before: Tsinghua Yuanxing Biomedicine Tech Co., Ltd., Shenzhen |
|
| DD01 | Delivery of document by public notice |
Addressee: Wang Lingjiang Document name: Notification of Passing Examination on Formalities |
|
| ASS | Succession or assignment of patent right |
Owner name: SHENZHEN YUANXING NANO-PHARMA CO.,LTD. Free format text: FORMER OWNER: SHENZHEN YUANXING BIO-PHARM CO., LTD. Effective date: 20150909 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20150909 Address after: 518000 Guangdong city of Shenzhen province Nanshan District high tech Industrial Park, North Central Avenue, North Song Ping Road No. 1 Lite technology building south 10 layer 1001 Patentee after: Shenzhen Yuanxing Nano-Pharmaceutical Co., Ltd. Address before: 518057 Lang Shan Road, North District, Nanshan District hi tech Development Zone, Guangdong, Shenzhen Patentee before: Shenzhen Yuanxing Bio-Pharm Co., Ltd. |
|
| DD01 | Delivery of document by public notice |
Addressee: Wang Lingjiang Document name: Notification of Passing Examination on Formalities |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041006 Termination date: 20160622 |